

# PROVIDER Update



Health Net®  
COMMUNITY SOLUTIONS

CONTRACTUAL | JUNE 27, 2018 | UPDATE 18-389 | 3 PAGES

## Medical Policies – 1st Quarter 2018

This provider update includes a listing of new and updated Health Net Community Solutions, Inc. (Health Net) medical policies approved by Centene's Corporate Clinical Policy Committee and/or Health Net's Medical Advisory Council (MAC) in the first quarter of 2018. For a complete description of the updated medical policies, visit the Health Net provider website at [provider.healthnet.com](http://provider.healthnet.com) and select *Working with Health Net > Clinical > Medical Policies*.

As Health Net integrates with Centene, Health Net medical policies are in the process of being replaced with Centene clinical policies, which are accessible via the website noted above.

### PURPOSE OF HEALTH NET MEDICAL POLICIES

Medical policies provide guidelines for determining medical necessity for specific procedures, equipment and services. For Medicare Advantage plans, apply the Medicare national and local policies for primary coverage guidance. All services must be medically necessary to be eligible for benefit coverage, unless otherwise defined in the member's individual benefits contract. The *Cal MediConnect Member Handbook* is the portion of the benefits contract that delineates the member's benefits in addition to eligibility requirements, and coverage exclusions and limitations. In some cases, legal or regulatory mandates may be applicable and may prevail over medical policy. To the extent there are any conflicts between medical policy guidelines and applicable benefits contract language, the benefits contract language prevails. Medical policy is not intended to override the member benefits contract that defines the member's benefits, nor is it intended to provide medical advice or dictate to providers how to practice. If required, prior authorization must be obtained before services are rendered.

### New Policies

Medical Policy	Policy Statement
<b>AMBULATORY SURGERY CENTER OPTIMIZATION</b>	This policy provides guidance for medically appropriate surgical procedures that can be provided in an ambulatory surgery center (ASC) instead of an inpatient or outpatient hospital setting
<b>CARDIAC BIOMARKER TESTING IN ACUTE MI</b>	Troponin I or T testing is medically necessary for suspected acute myocardial infarctions (AMI). Creatine kinase myocardial isoenzyme (CK-MB) and myoglobin testing are considered not medically necessary for suspected AMI
<b>EEG FOR HEADACHE</b>	An electroencephalogram (EEG) is considered not medically necessary for the routine evaluation of a headache

THIS UPDATE APPLIES TO  
**CAL MEDICCONNECT**  
PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

### PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)  
Los Angeles County – 1-855-464-3571  
San Diego County – 1-855-464-3572  
[www.healthnet.com](http://www.healthnet.com)

### PROVIDER COMMUNICATIONS

[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)  
healthnet.com  
fax 1-800-937-6086

### New Policies, continued

Medical Policy	Policy Statement
<b>H. PYLORI SEROLOGY TESTING</b>	H. pylori serology testing is not medically necessary for diagnosing infection or evaluating treatment effectiveness
<b>HOME PHOTOTHERAPY FOR NEONATAL HYPERBILIRUBINEMIA</b>	This policy notes the guidelines when conventional phototherapy, applied by a single light source in the blue-green spectrum, is medically appropriate in a home setting for the treatment of physiologic hyperbilirubinemia in term ( $\geq 38$ weeks gestation) stable infants. Refer to the policy for additional details
<b>THYROID AND INSULIN TESTING IN PEDIATRICS</b>	Thyroid and insulin testing in healthy, or in obese but otherwise healthy, children (ages 1 to 18) are not considered medically necessary
<b>TRANSCATHETER CLOSURE OF PATENT FORAMEN OVALE</b>	Percutaneous transcatheter closure of patent foramen ovale (PFO) with a U.S. Food and Drug Administration- (FDA-) approved device is considered medically necessary to reduce the risk of recurrent ischemic stroke when the indications in the policy are met. It is considered experimental/investigational for migraine prophylaxis, stroke prevention or unexplained oxygen desaturation
<b>VITAMIN D TESTING IN PEDIATRIC POPULATION</b>	This policy states that 25-hydroxyvitamin D testing in healthy, including obese but otherwise healthy, children (ages 1 to 18) is considered not medically necessary

### Updated Policies

Medical Policy	Change
<b>APPLIED BEHAVIORAL ANALYSIS (ABA)</b>	Revised I.C.2 to state that lead poisoning rather than heavy metal poisoning has been ruled out per the American Academy of Neurology
<b>AUTOMATED AMBULATORY BLOOD PRESSURE MONITORING</b>	Revised blood pressure (BP) thresholds from greater than 140/90 to greater than 130/80 based on pending publication of the American College of Cardiology recommendations
<b>DOUBLE BALLOON ENTEROSCOPY</b>	Per the American Society for Gastrointestinal Endoscopy, added medically appropriate diagnoses when diseases of the small bowel are suspected and conventional diagnostic tests are negative
<b>DME</b>	Added criteria for prolonged and intermittent infusions under Ambulatory infusion pump, section D
<b>FECAL INCONTINENCE TREATMENT</b>	Added II.E. Vaginal bowel control (such as Eclipse system) as investigational
<b>HYPERBARIC OXYGEN THERAPY</b>	Added idiopathic sudden sensorineural hearing loss and central retinal artery occlusion as indications, expanded antimycotic brain abscess to intracranial abscess and added criteria per Undersea and Hyperbaric Medicine Society (UHMS)
<b>HYPEREMESIS GRAVIDARUM TREATMENT</b>	Per the American College of Obstetricians and Gynecologists (ACOG), revised dosage of dimenhydrinate in table 1 for initial therapy, added trimethobenzamide IM to table 1 for initial therapy. Added dimenhydrinate IV to Step 2 in table 1

**Updated Policies, continued**

Medical Policy	Change
<b>NONMYELOABLATIVE ALLOGENIC TRANSPLANT</b>	Clarified under Policy/Criteria I. that policy statements apply to reduced-intensity conditioning and non-myeloablative regimens. Added paroxysmal nocturnal hemoglobinuria and myelofibrosis as indications. Changed chronic lymphoblastic leukemia to chronic lymphocytic leukemia. Added criteria to multiple myeloma requiring that it be responsive to primary treatment. For myelodysplastic syndromes, restricted indication to adults. Removed contraindication in II.A. of ineligibility for conventional high-dose chemotherapy/myeloablation, as well as restriction for members under age 3
<b>OBSTETRICAL HOME HEALTH PROGRAMS</b>	Premature replaced by prelabor rupture of membranes per ACOG revitalize obstetric data definitions. Replaced Makena® with hydroxyprogesterone caproate
<b>PANCREAS TRANSPLANT</b>	Removed islet cell transplantation from III
<b>PEDIATRIC HEART TRANSPLANTATION</b>	Added AL amyloidosis as a contraindication
<b>REFRACTIVE SURGERY (LASIK, LESEK, PRK, PARK AND PRK-A)</b>	Added that epikeratoplasty is considered medically necessary for acquired or congenital aphakia
<b>VITAMIN D, MEASUREMENT OF SERUM</b>	This policy addresses when the measurement of 1,25(OH)2D is appropriate and medically necessary for monitoring certain conditions, such as acquired and inherited disorders of vitamin D and phosphate metabolism

**ADDITIONAL INFORMATION**

Providers are encouraged to access Health Net's provider portal online at [provider.healthnet.com](http://provider.healthnet.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by county within 60 days at:

Line of Business	Telephone Number	Email Address
<b>CAL MEDICONNECT – LOS ANGELES COUNTY</b>	1-855-464-3571	provider_services@healthnet.com
<b>CAL MEDICONNECT – SAN DIEGO COUNTY</b>	1-855-464-3572	